Moderna

  • MRNA

  • $38.34

  • +3.79%

  • $36.55

  • $38.82

  • $35.96

QUANT_RATINGS

Ticker Appearances

Thu, September 12, 2024 | 11:52AM ET

⚡ FlashInsights

Thu, September 12, 2024 | 11:52AM ET
Mark
Mark L. Newton, CMT AC

Head of Technical Strategy
🔥 🔥 🔥
CPI and PPI data resulted in some volatility this week for Equities, but largely have locked in the outcome of next week's Fed meeting with a 25 bp cut, if the rate cut bets of the Swap market positioning is any guide. Whether or not we see a subsequent 50 bp the following meeting and Rate cuts follow the markets 200 bp into next June is open to argument, but for now, economic data has stabilized somewhat in the last month, and Treasury yields seem to be taking their cue more from labor mkt data than inflation. Equities are mildly higher today, thanks to 6 positive sectors out of 11 and breadth is around 2/1 positive. Yet, its the slightly negative move out of Technology (A 2.71% , MU 4.66%  LRCX 4.67% , STX 2.84%  big laggards) and Healthcare weakness (MRNA 3.79% , WAT 3.00% , TMO 0.72% , PFE 0.56% ) thats causing benchmark indices not to be higher.

Daily Technical Strategy
Mon, May 13, 2024 | 6:37PM ET
Mark
Mark L. Newton, CMT AC

Head of Technical Strategy

AAPL behavior gives confidence ahead of this week’s CPI print

EQUITIES HAVE EXTENDED GAINS AND HAVE NOW COME WITHIN STRIKING DISTANCE OF LATE MARCH PEAKS.   SPX HAS NEARLY RECAPTURED ALL OF THE PERIOD OF WEAKNESS...

This report is accessible to
FSI Pro, FSI Macro memberships.

You have viewed the limit of 2 reports for free this month.

To continue reading our research please sign up below.

Already have an account? Sign In

Visitor: c01fca-3326dd-362905-fc3074-68d8f3

First to Market
Wed, May 8, 2024 | 8:36AM ET
Group135
FS Insight Team

Three Important Things

A daily market update from FS Insight — what you need to know ahead of opening bell “Three things in human life are important: the...

This report is accessible to
FSI Pro, FSI Macro memberships.

You have viewed the limit of 2 reports for free this month.

To continue reading our research please sign up below.

Already have an account? Sign In

Visitor: c01fca-3326dd-362905-fc3074-68d8f3

Mon, March 11, 2024 | 3:27PM ET

⚡ FlashInsights

Mon, March 11, 2024 | 3:27PM ET
Mark
Mark L. Newton, CMT AC

Head of Technical Strategy
🔥 🔥 🔥
Could vaccine maker Moderna finally be on the road to recovery? MRNA 3.79%  is higher by +9.94% today the best performing name in the ^SPX 0.44%  after the Drugmaker is starting a mid-stage study to test its experimental cancer vaccine in patients with skin cancer. This trial is in collaboration with Merck. Technically speaking, a move above $116 would allow for the lengthy downtrend to be exceeded and would also allow MRNA to recapture and surpass its January 2024 peaks, (as well as former lows from 2022) which would give a technical "green light" to the idea that further gains could happen. Upside targets above $116 on a weekly close would project to $170 initially and then $213-20
Tickers

Events

Tickers

Trending tickers in our research